MARKER THERAPEUTICS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
MARKER THERAPEUTICS, INC. (MRKR) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) of -$31.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-09.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease · last filed 2021-03-09
- MARKER THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2020-12-31 was $0.00.
- MARKER THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- MARKER THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- MARKER THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2020-03-31 was -$31.00K, a 444.44% decline year-over-year.
- MARKER THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2020 was -$31.00K.
- MARKER THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2019 was -$18.00K, a 145.00% decline from fiscal 2018.
- MARKER THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2018 was $40.00K.
- MARKER THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2017 was -$5.50K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $0.00 derived: sum of 2 quarters · filed 2021-03-09 | $0.00 derived: sum of 3 quarters · filed 2021-03-09 | -$31.00K 10-K · filed 2021-03-09 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | -$31.00K 10-Q · filed 2020-11-09 | -$129.00K derived: sum of 4 quarters · filed 2021-03-09 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$31.00K 10-Q · filed 2020-08-10 | -$129.00K derived: sum of 3 quarters · filed 2021-03-09 | -$65.00K derived: sum of 4 quarters · filed 2021-03-09 |
| 2020-03-31 | -$31.00K 10-Q · filed 2020-05-11 | -$129.00K derived: sum of 2 quarters · filed 2021-03-09 | -$65.00K derived: sum of 3 quarters · filed 2021-03-09 | -$58.00K derived: sum of 4 quarters · filed 2021-03-09 |
| 2019-12-31 | -$98.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | -$34.00K derived: sum of 2 quarters · filed 2021-03-09 | -$27.00K derived: sum of 3 quarters · filed 2021-03-09 | -$18.00K 10-K · filed 2021-03-09 |
| 2019-09-30 | $64.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $71.00K derived: sum of 2 quarters · filed 2019-11-12 | $80.00K 10-Q · filed 2019-11-12 | $22.00K derived: sum of 4 quarters · filed 2020-03-12 |
| 2019-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $16.00K 10-Q · filed 2019-08-09 | -$42.00K derived: sum of 3 quarters · filed 2020-03-12 | -$82.00K derived: sum of 4 quarters · filed 2020-03-12 |
| 2019-03-31 | $9.00K 10-Q · filed 2019-05-10 | -$49.00K derived: sum of 2 quarters · filed 2020-03-12 | -$89.00K derived: sum of 3 quarters · filed 2020-03-12 | $50.00K derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-12-31 | -$58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$98.00K derived: sum of 2 quarters · filed 2020-03-12 | $41.00K derived: sum of 3 quarters · filed 2020-03-12 | $40.00K 10-K · filed 2020-03-12 |
| 2018-09-30 | -$40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $99.00K derived: sum of 2 quarters · filed 2018-11-13 | $98.00K 10-Q · filed 2018-11-13 | $101.00K derived: sum of 4 quarters · filed 2019-03-15 |
| 2018-06-30 | $139.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $138.00K 10-Q · filed 2018-08-09 | $141.00K derived: sum of 3 quarters · filed 2019-03-15 | $137.00K derived: sum of 4 quarters · filed 2019-03-15 |
| 2018-03-31 | -$1.00K 10-Q · filed 2018-05-15 | $2.00K derived: sum of 2 quarters · filed 2019-03-15 | -$2.00K derived: sum of 3 quarters · filed 2019-03-15 | -$9.50K derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | -$1.00K derived: sum of 2 quarters · filed 2019-03-15 | -$8.50K derived: sum of 3 quarters · filed 2019-03-15 | -$5.50K 10-K · filed 2019-03-15 |
| 2017-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | -$11.50K derived: sum of 2 quarters · filed 2017-11-14 | -$8.50K 10-Q · filed 2017-11-14 | -$23.00K derived: sum of 4 quarters · filed 2018-03-23 |
| 2017-06-30 | -$7.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | -$4.50K 10-Q · filed 2017-08-07 | -$19.00K derived: sum of 3 quarters · filed 2018-03-23 | |
| 2017-03-31 | $3.00K 10-Q · filed 2017-05-05 | -$11.50K derived: sum of 2 quarters · filed 2018-03-23 | ||
| 2016-12-31 | -$14.50K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-23 | -$5.94M 10-K · filed 2018-03-23 | ||
| 2016-09-30 | -$5.92M 10-Q · filed 2016-11-04 | |||
| 2015-12-31 | $27.87M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |